Amgen Partners With Daiichi-Sankyo For Denosumab In Japan
This article was originally published in PharmAsia News
Executive Summary
Amgen and Daiichi-Sankyo have entered a collaboration and license agreement for development and commercialization of Amgen's investigational bone loss therapy denosumab in Japan, the companies announced July 11
You may also be interested in...
After A Dry 2013, Daiichi Sankyo Looks To Partners To Make It Rain
With only one deal in the last year, Daiichi Sankyo is ready for more deal-making with a new biz dev head and the acquisitions of oncology company Plexxikon and generics play Ranbaxy well behind it.
Daiichi Nets Novel HER-3 Antibody With U3 Acquisition
Daiichi Sankyo will acquire the privately held German biotech U3 Pharma in a €150 million ($233.9 million) deal that includes a novel HER-3 receptor antagonist partnered with Amgen
Daiichi Nets Novel HER-3 Antibody With U3 Acquisition
Daiichi Sankyo will acquire the privately held German biotech U3 Pharma in a €150 million ($233.9 million) deal that includes a novel HER-3 receptor antagonist partnered with Amgen